Beraprost Sodium, a Prostaglandin I2 Analogue, Protects Against Advanced Glycation End Products-induced Injury in Cultured Retinal Pericytes
Beraprost sodium, a prostaglandin I2 analogue, has been recently reported to exhibit beneficial effects on atherosclerosis in patients with diabetes. However, effects of beraprost sodium on microvascular injury in diabetes remain to be elucidated. We have previously shown that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, caused pericyte apoptosis, thus being involved in the pathogenesis of the early phase of diabetic retinopathy. In this study, we examined whether beraprost sodium can protect against AGE-induced cytotoxicity in cultured retinal pericytes.
Materials and Methods
Intracellular formation of reactive oxygen species (ROS) was detected using a fluorescent probe. DNA synthesis was determined by measuring [3H]thymidine incorporation into cells. Apoptosis was determined by DNA fragmentations, which were quantitatively measured in an enzyme-linked immunosorbent assay.
Beraprost sodium or forskolin, a stimulator of adenylate cyclase, was found to significantly inhibit AGE-induced ROS generation and the subsequent decrease in DNA synthesis in pericytes. Both treatments significantly prevented AGE-induced apoptotic cell death in pericytes. Furthermore, beraprost sodium was found to down-regulate AGE receptor mRNA levels in pericytes.
The results demonstrated that cyclic AMP-elevating agents such as beraprost sodium and forskolin protected retinal pericytes from AGE-induced cytotoxicity through its anti-oxidative properties. Our present study suggests that beraprost sodium may have therapeutic potentials in treatment of patients with early diabetic retinopathy.
This work was supported in part by Grants (S.Y.) from Venture Research and Development Centers from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Suzuken Memorial Foundation, Japan and the Mochida Memorial Foundation for Medical and Pharmaceutical Research, Japan.
- 5.LíEsperance FA, James WA, Judson PH. (1990) The eye and diabetes mellitus. In: Ellenberg and Rifkinís Diabetes Mellitus, Theory and Practice, ed. Lifkin H, Porte D, Elsevier, New York, NY, pp. 661–683.Google Scholar
- 16.Yamagishi S, Yonekura H, Yamamoto Y, et al. (1997) Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272: 8723–8730.CrossRefPubMedGoogle Scholar